

Iacopo Baussano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5899702/publications.pdf>

Version: 2024-02-01

62
papers

2,679
citations

279798

23
h-index

197818

49
g-index

70
all docs

70
docs citations

70
times ranked

3557
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimates of the global burden of cervical cancer associated with HIV. <i>The Lancet Global Health</i> , 2021, 9, e161-e169.	6.3	319
2	Tuberculosis among Health Care Workers. <i>Emerging Infectious Diseases</i> , 2011, 17, 488-494.	4.3	263
3	Tuberculosis Incidence in Prisons: A Systematic Review. <i>PLoS Medicine</i> , 2010, 7, e1000381.	8.4	258
4	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. <i>Lancet Public Health</i> , The, 2016, 1, e8-e17.	10.0	210
5	Continuous Positive Airway Pressure for Treatment of Respiratory Complications After Abdominal Surgery. <i>Annals of Surgery</i> , 2008, 247, 617-626.	4.2	154
6	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 119-132.	27.6	154
7	Evaluation of Immigrant Tuberculosis Screening in Industrialized Countries. <i>Emerging Infectious Diseases</i> , 2012, 18, 1422-1429.	4.3	90
8	Feasibility of recruiting a birth cohort through the Internet: the experience of the NINFEA cohort. <i>European Journal of Epidemiology</i> , 2007, 22, 831-837.	5.7	83
9	Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. <i>Journal of Infectious Diseases</i> , 2016, 213, 199-205.	4.0	56
10	Introduction of a National HPV vaccination program into Bhutan. <i>Vaccine</i> , 2015, 33, 3726-3730.	3.8	51
11	Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference. <i>Preventive Medicine</i> , 2017, 98, 21-30.	3.4	49
12	Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). <i>International Journal of Cancer</i> , 2018, 143, 2299-2310.	5.1	46
13	Impact of gender-neutral or girls-only vaccination against human papillomavirus—Results of a community-randomized clinical trial (I). <i>International Journal of Cancer</i> , 2018, 142, 949-958.	5.1	42
14	Eradication of human papillomavirus and elimination of HPV-related diseases – scientific basis for global public health policies. <i>Expert Review of Vaccines</i> , 2019, 18, 153-160.	4.4	41
15	Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. <i>Vaccine</i> , 2015, 33, 1284-1290.	3.8	40
16	Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme. <i>BMC Infectious Diseases</i> , 2016, 16, 225.	2.9	40
17	Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. <i>Lancet Public Health</i> , The, 2021, 6, e510-e521.	10.0	39
18	Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. <i>International Journal of Cancer</i> , 2016, 139, 518-526.	5.1	38

#	ARTICLE	IF	CITATIONS
19	Risk of tuberculin conversion among healthcare workers and the adoption of preventive measures. <i>Occupational and Environmental Medicine</i> , 2007, 64, 161-166.	2.8	34
20	Cancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation. <i>JCO Global Oncology</i> , 2021, 7, 416-424.	1.8	34
21	Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1598-1610.	9.1	34
22	Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. <i>Journal of Infectious Diseases</i> , 2020, 222, 948-956.	4.0	29
23	HPV-16 infection and cervical cancer: Modeling the influence of duration of infection and precancerous lesions. <i>Epidemics</i> , 2010, 2, 21-28.	3.0	27
24	Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort. <i>Vaccine</i> , 2020, 38, 4001-4005.	3.8	27
25	Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. <i>Vaccine</i> , 2011, 29, 1270-1277.	3.8	24
26	Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status. <i>International Journal of Cancer</i> , 2020, 146, 1514-1522.	5.1	23
27	Neonatal Screening for Cystic Fibrosis Does Not Affect Time to First Infection With <i>Pseudomonas aeruginosa</i> . <i>Pediatrics</i> , 2006, 118, 888-895.	2.1	22
28	Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme. <i>BMC Infectious Diseases</i> , 2014, 14, 408.	2.9	22
29	Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30 years in Bhutan. <i>Virology Journal</i> , 2017, 14, 74.	3.4	22
30	Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates. <i>PLoS ONE</i> , 2013, 8, e81171.	2.5	21
31	Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan. <i>Emerging Infectious Diseases</i> , 2020, 27, 1-9.	4.3	21
32	Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior. <i>Emerging Infectious Diseases</i> , 2016, 22, 18-23.	4.3	20
33	Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 336-344.	4.0	20
34	Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine. <i>PLoS ONE</i> , 2013, 8, e75552.	2.5	19
35	Age-specific burden of cervical cancer associated with HIV: A global analysis with a focus on sub-Saharan Africa. <i>International Journal of Cancer</i> , 2022, 150, 761-772.	5.1	19
36	Impacts of human papillomavirus vaccination for different populations: A modeling study. <i>International Journal of Cancer</i> , 2018, 143, 1086-1092.	5.1	18

#	ARTICLE	IF	CITATIONS
37	Evaluation of human-papillomavirus testing and visual inspection for cervical cancer screening in Rwanda. <i>BMC Women's Health</i> , 2018, 18, 59.	2.0	18
38	Comparison of HPV DNA testing in cervical exfoliated cells and tissue biopsies among HIV-positive women in Kenya. <i>International Journal of Cancer</i> , 2013, 133, 1441-1446.	5.1	17
39	High Rates of <i>Mycobacterium tuberculosis</i> among Socially Marginalized Immigrants in Low-Incidence Area, 1991â€“2010, Italy. <i>Emerging Infectious Diseases</i> , 2013, 19, 1437-1445.	4.3	17
40	The role and utility of population-based cancer registries in cervical cancer surveillance and control. <i>Preventive Medicine</i> , 2021, 144, 106237.	3.4	17
41	Naturally Acquired Immunity Against Human Papillomavirus (HPV): Why It Matters in the HPV Vaccine Era. <i>Journal of Infectious Diseases</i> , 2014, 210, 507-509.	4.0	16
42	The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. <i>Lancet Public Health</i> , The, 2020, 5, e592-e603.	10.0	16
43	Cervical cancer screening in rural Bhutan with the <i>care</i> HPV test on self-collected samples: an ongoing cross-sectional, population-based study (REACH-Bhutan). <i>BMJ Open</i> , 2017, 7, e016309.	1.9	15
44	Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries. <i>International Journal of Cancer</i> , 2013, 133, 1876-1881.	5.1	14
45	Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. <i>Infectious Agents and Cancer</i> , 2014, 9, 4.	2.6	14
46	Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011â€“2012 and 2018. <i>Annals of Internal Medicine</i> , 2020, 173, 888-894.	3.9	14
47	Does language matter? A case study of epidemiological and public health journals, databases and professional education in French, German and Italian. <i>Emerging Themes in Epidemiology</i> , 2008, 5, 16.	2.7	13
48	Options for design of real-world impact studies of single-dose vaccine schedules. <i>Vaccine</i> , 2018, 36, 4816-4822.	3.8	11
49	Modelling cervical cancer elimination. <i>Lancet Public Health</i> , The, 2019, 4, e2-e3.	10.0	11
50	Yield of tuberculosis contact investigation in a low-incidence country. <i>Journal of Infection</i> , 2014, 68, 448-454.	3.3	10
51	Prospects for accelerated elimination of cervical cancer. <i>Preventive Medicine</i> , 2021, 153, 106827.	3.4	9
52	Cervical cancer screening program in Thimphu, Bhutan: population coverage and characteristics associated with screening attendance. <i>BMC Women's Health</i> , 2014, 14, 147.	2.0	8
53	Baseline findings and safety of infrequent <i>vs</i> frequent screening of human papillomavirus vaccinated women. <i>International Journal of Cancer</i> , 2020, 147, 440-447.	5.1	8
54	Evaluation of cytology versus human papillomavirus-based cervical cancer screening algorithms in Bhutan. <i>Oncotarget</i> , 2017, 8, 72438-72446.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Predicting Cohort-Specific Cervical Cancer Incidence From Population-Based Surveys of Human Papilloma Virus Prevalence: A Worldwide Study. <i>American Journal of Epidemiology</i> , 2022, 191, 402-412.	3.4	7
56	Expected number of childhood cancers in Italy from 2001 to 2015. <i>Haematologica</i> , 2007, 92, 1258-1261.	3.5	6
57	Effect of age-difference between heterosexual partners on risk of cervical cancer and human papillomavirus infection. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 98-104.	4.5	6
58	Estimating Total Excess Mortality During a Coronavirus Disease 2019 Outbreak in Stockholm, Sweden. <i>Clinical Infectious Diseases</i> , 2021, 72, e890-e892.	5.8	5
59	Causal system modelling of cervical cancer screening. <i>Lancet Public Health, The</i> , 2017, 2, e61-e62.	10.0	1
60	Prevention is life- and cost-saving. <i>Preventive Medicine</i> , 2020, 138, 106150.	3.4	1
61	Neonatal Screening for Cystic Fibrosis Does Not Affect Time to First Infection with <i>Pseudomonas aeruginosa</i> . <i>Obstetrical and Gynecological Survey</i> , 2007, 62, 20-21.	0.4	0
62	Outcomes of a tuberculosis contact investigation programme in Italy. <i>European Respiratory Journal</i> , 2012, 40, 1291-1293.	6.7	0